Scottsdale, Arizona & Boca Raton, Florida, August 4, 2026
CND Life Sciences has announced the successful completion of a growth financing round led by S-Curve Partners, providing new capital to accelerate the expansion of its Syn-One Test® platform and strengthen the company’s broader precision neurology strategy. Existing investors and shareholders also participated in the financing, demonstrating continued confidence in the company’s commercial momentum, expanding clinical adoption and long-term growth strategy. The investment will support expansion of the Syn-One Test, the first commercially available skin biopsy-based laboratory developed test (LDT) designed to detect phosphorylated alpha-synuclein and other pathological biomarkers associated with neurodegenerative diseases. Since its commercial introduction in 2020, the platform has been adopted by more than 4,000 neurologists and healthcare providers across the United States and has supported the diagnostic evaluation of over 60,000 patients with suspected Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, REM sleep behavior disorder, and related synucleinopathies. The financing underscores growing industry interest in objective biomarkers, precision diagnostics, and earlier disease detection across neurology.
Growth Financing Expands Precision Neurology Platform
The newly completed financing will enable CND Life Sciences to accelerate commercial expansion of the Syn-One Test while advancing product innovation, strategic collaborations and broader multimodal biomarker capabilities. Company leadership indicated that the investment will support continued growth of its commercial operations, strengthen relationships with pharmaceutical companies and research organizations, and expand development of diagnostic solutions capable of improving disease characterization across neurodegenerative disorders. As the field of neurology increasingly shifts toward precision medicine, objective biomarker technologies are becoming essential tools for improving diagnostic confidence, supporting therapeutic decision-making and identifying patients earlier in the disease course. The company plans to leverage the funding to further integrate the Syn-One platform into comprehensive diagnostic approaches combining multiple biomarkers to improve clinical evaluation of complex neurological conditions.
Syn-One Test Advances Biomarker-Based Neurological Diagnosis
The Syn-One Test® represents a significant advancement in neurodiagnostics, utilizing a minimally invasive skin biopsy to detect abnormal phosphorylated alpha-synuclein, a pathological protein strongly associated with several synucleinopathies. The laboratory-developed test provides clinicians with objective pathological information that complements clinical examination and other diagnostic assessments when evaluating patients with suspected Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and related disorders. Supported by an expanding body of peer-reviewed clinical evidence, the platform has gained widespread clinical adoption since its launch, reflecting increasing demand for reliable biomarkers capable of improving diagnostic accuracy in neurodegenerative diseases that are frequently underdiagnosed or misdiagnosed. Beyond routine clinical practice, the company continues collaborating with biopharmaceutical companies to support clinical trials, investigational therapies, early disease detection studies and research focused on quantitative alpha-synuclein biomarkers.
Advertisement
Investment Strengthens Future of Precision Neurodiagnostics
The financing reflects growing investor confidence in the expanding role of biomarker-driven diagnostics within neuroscience and personalized medicine. As disease-modifying therapies continue to emerge for neurodegenerative disorders, earlier and more accurate diagnosis has become increasingly important for clinicians, patients and pharmaceutical developers. S-Curve Partners noted that objective biomarker technologies are expected to play a central role in improving disease differentiation, accelerating therapeutic development and supporting personalized treatment strategies. By combining commercial expansion with ongoing scientific innovation, CND Life Sciences aims to transform the Syn-One Test from a category-leading diagnostic product into a broader precision neurology platform capable of supporting earlier diagnosis, disease monitoring and improved patient management. The latest investment positions the company to continue advancing biomarker-based diagnostics while strengthening collaborations across the healthcare, pharmaceutical and clinical research communities to address the growing global burden of neurodegenerative disease.
Source: CND Life Sciences press release
